Results 221 to 230 of about 89,766 (303)

GB20-5A8-31, an anti-TL1A antibody for treating inflammatory bowel disease. [PDF]

Front Immunol
Huang Y, You Q, Yao T, Tong Y, Yang X, Zhang X, Huang X, Chen Q, Lu F, Li H, Wang J, Qin S.   +11 more
europepmc   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Alzheimer's disease: from molecular pathways to therapies. [PDF]

Mol Biomed
Feng JQ, Yang LL, Luo YX, Yao XQ.
europepmc   +1 more source

CRISPR Genome Editing and the Future of Leukaemia Immunotherapy

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Leukaemia presents ongoing therapeutic challenges due to relapse and toxicity associated with standard treatments. By enabling more targeted and safer therapies, CRISPR genome editing is emerging as a powerful tool to address these issues.
Dejin Rai, Umberto Terranova
wiley   +1 more source

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis. [PDF]

Eur J Immunol
Khodadadi L, Puppe D, Cirillo DS, Martinez-Cingolani C, Klotsche J, Pelz A, Kohler S, Cheng Q, Lazaridis K, Fichtner M, Pille J, Kruglov A, Bondareva M, Alexander T, Radbruch A, Meisel A, Hiepe F.   +16 more
europepmc   +1 more source

Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms

JPGN Reports, Volume 7, Issue 2, Page 185-191, May 2026.
Abstract Objectives Eosinophilic esophagitis (EoE) is a type 2 cytokine‐mediated chronic inflammatory condition leading to esophageal dysfunction. Dupilumab blocks IL‐4 and IL‐13 signaling, which are key inflammatory mediators in EoE and other allergic disorders.
Sindhura Kasturi, Tanaz Danialifar, Thirumazhisai Gunasekaran, Nick Shillingford, Paul Zamiara, Vrinda Bhardwaj, Melinda Braskett   +6 more
wiley   +1 more source

CAR‐T Cells: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 5, May 2026.
This graphical abstract outlines the current status, challenges, and future prospects of CAR‐T cells. The biological basis of CAR‐T cell therapy is the elegant redirection of adaptive immunity. Its initial successes have exposed a landscape of multifaceted challenges.
Aya Sedky Adly, Guillaume Cartron, Afnan Sedky Adly, Jean‐Christophe Egea, Pierre‐Yves Collart Dutilleul, Mahmoud Sedky Adly, Martin Villalba   +6 more
wiley   +1 more source

Novel immunotherapeutic strategies for diffuse large B-cell lymphoma: a comprehensive review. [PDF]

Front Immunol
Li Y, Zhang Y, Zhu C, Han Y, Gao X, Yue J, Wang Y.   +6 more
europepmc   +1 more source

Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies

MedComm, Volume 7, Issue 5, May 2026.
The mechanism of multiple signaling pathways and their related targeted inhibitors in HCC. (A) The mechanism of Ras/Raf/MEK/ERK signaling pathway and its related targeted inhibitors; (B) the mechanism of PI3K/AKT/mTOR signaling pathway and its crosstalk with other pathways and its related targeted inhibitors; (C) the mechanism of JAK/STAT signaling ...
Penghui He, Sinan Xie, Kunlin Xie, Fengwei Gao, Yunshi Cai, Yan Huang, Chang Liu, Hong Wu, Yinghao Lyu, Tian Lan   +9 more
wiley   +1 more source

A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer. [PDF]

J Transl Med
Xu F, Liu W, Su L, Yang L, Zhang Y, Liu B, Liu S, Liu Z, Chen Z, Lu Y, Zhang N, Huang R, Zhao H, Song W.   +13 more
europepmc   +1 more source